comparemela.com

Latest Breaking News On - Yves brulard - Page 1 : comparemela.com

BioSenic S A : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles

PRESS RELEASE - PRIVILEGED INFORMATION After a recent circular consultation of the creditors, based on XX 83/23 of the Economic Law Code , the Enterprise Court of Nivelles registers today the.

BioSenic S A : Positive vote of the majority of creditors in favor of the global restructuring plan of BioSenic covering the years 2024-2032, at the Enterprise Court of Nivelles

PRESS RELEASE - PRIVILEGED INFORMATION After a recent circular consultation of the creditors, based on XX 83/23 of the Economic Law Code (ELC), the Enterprise Court of Nivelles registers today the

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles

BioSenic publishes on its website the restructuring plan submitted to the Enterprise Court of Nivelles
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

BioSenic reaches agreement on binding term sheets with main creditors to restructure past financial debts

INSIDE INFORMATION New binding term sheets have been formulated upon for the replacement of the Monument and Patronale bonds and loans by new unsecured convertible bonds as well as for the long-term extension of the past loan financing with the European Investment Bank. Mont-Saint-Guibert, Belgium, September 14, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announc

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.